Trial Profile
A Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction With Platinum-Based Chemotherapy Combined With Durvalumab, for the First-Line Treatment of Patients With Extensive Stage Small-Cell Lung Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 11 Sep 2023
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Defosbarasertib (Primary) ; Durvalumab (Primary) ; Etoposide (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms TAZMAN
- Sponsors AstraZeneca
- 08 Sep 2023 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 09 Sep 2022 Planned End Date changed from 31 Oct 2023 to 31 Mar 2023.
- 03 Feb 2022 Planned End Date changed from 11 Mar 2024 to 31 Oct 2023.